1215493-56-3 Usage
Description
RGFP 109 is a histone deacetylase (HDAC) inhibitor, which is a type of compound that can interfere with the function of histone deacetylases. These enzymes are involved in the regulation of gene expression by modifying the structure of chromatin, the complex of DNA and protein found in cell nuclei. By inhibiting HDACs, RGFP 109 can potentially influence gene expression and has been studied for its effects on reversing gene silencing in certain diseases.
Uses
Used in Pharmaceutical Industry:
RGFP 109 is used as a therapeutic agent for the treatment of Friedreich ataxia (FRDA), a genetic disorder characterized by progressive damage to the nervous system. RGFP 109 acts as an HDAC inhibitor, which has been shown to reverse the silencing of the FXN gene in short-term studies of FRDA patient cells. This gene plays a crucial role in the production of a protein necessary for proper functioning of the nervous system, and its silencing is associated with the development of FRDA. By reversing this gene silencing, RGFP 109 may help alleviate the symptoms and slow the progression of the disease.
Additionally, due to its HDAC inhibitory properties, RGFP 109 may have potential applications in other areas of medicine where HDAC inhibition could be beneficial, such as cancer therapy, neurodegenerative diseases, and cardiovascular conditions. However, further research would be required to explore these potential applications and establish the safety and efficacy of RGFP 109 in these contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 1215493-56-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,5,4,9 and 3 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1215493-56:
(9*1)+(8*2)+(7*1)+(6*5)+(5*4)+(4*9)+(3*3)+(2*5)+(1*6)=143
143 % 10 = 3
So 1215493-56-3 is a valid CAS Registry Number.
1215493-56-3Relevant articles and documents
Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
-
, (2012/04/23)
This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
